Sepsis

NeoVanc, a European trial featured in The Lancet Child & Adolescent Health, has published the findings of the largest neonatal vancomycin efficacy trial ever conducted. NeoVanc was a European, multicentre research study coordinated by Penta and funded by the European Commission’s 7th Framework Programme. It compared the efficacy, safety and pharmacokinetics of an optimised dosing regimen with a standard dosing regimen of vancomycin in infants with late onset sepsis.

Padova – Italy, November  27th 2021

NeoVanc, a European trial featured in The Lancet Child & Adolescent Health, has published the findings of the largest neonatal vancomycin efficacy trial ever conducted:

• No clear benefit was seen with the use of an optimised short (5±1 day) course of vancomycin, including a loading dose, compared to a longer (10±2 day) standard course in babies treated for sepsis occurring in hospital,

The 13^th September marks World Sepsis Day. Infectious diseases remains a leading cause of death for children. The burden of this problem is particularly felt in sub-Saharan Africa and in Central and Southern Asia, due to the high prevalence of comorbidities.

Together with GARDP and St George’s University of London and partners across the world, we have collaborated on different projects aiming to develop and deliver innovative real world research that will be used to bring new and improved treatment and prevention options for babies and children that are affordable and available as fast as possible.

Aislinn Cook, a research fellow at St. George’s University of London in the Paediatric Infectious Diseases Research Group, is the winner of the ISF/ESCMID Sepsis Award 2020! The International Sepsis Forum (ISF) is a non-profit public American charity with the mission to improve outcomes for patients with sepsis. Aislinn was awarded this prize for her ECCMID2020 abstract on the NeoAMR Global Neonatal Sepsis Observational Study (NeoOBS).